Akcea Therapeutics is Biotechnology in United States that focus on Akcea Therapeutics Inc business. Founded in 2015. They cover business area such as Akcea Therapeutics Inc, drug, patient, serious cardiometabolic disease, lipid disorder, multiple disease, AKCEA-APO(a)-LRx, AKCEA-APOCIII-LRx, antisense technology, Ionis Pharmaceuticals, Inc., familial chylomicronemia syndrome, FCS, Phase, familial partial lipodystrophy, FPL.
2015
( 9 years old in 2024 )
Akcea Therapeutics Inc
-
22 Boston Wharf Road
9th Floor
Boston, MA 02210
United States
Private
Akcea Therapeutics Incdrugpatientserious cardiometabolic diseaselipid disordermultiple diseaseAKCEA-APO(a)-LRxAKCEA-APOCIII-LRxantisense technologyIonis PharmaceuticalsInc.familial chylomicronemia syndromeFCSPhasefamilial partial lipodystrophyFPL
* We use standard office opening hours in near Akcea Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Akcea Therapeutics is Biotechnology business from United States that founded in 2015 (9 years old in 2024), Akcea Therapeutics business is focusing on Akcea Therapeutics Inc.
Akcea Therapeutics headquarter office and corporate office address is located in 22 Boston Wharf Road 9th Floor Boston, MA 02210 United States.
Akcea Therapeutics was founded in United States.
In 2024, Akcea Therapeutics is currently focus on Akcea Therapeutics Inc sector.
Above is snippet of Google Trends for "Akcea Therapeutics Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Akcea Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
